Clinical trial
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic…
NCT02335411 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02335411 |
|---|---|
| Title | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) |
| Official title | A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma |
| Intervention type | Biological, Drug |
| Interventions | pembrolizumab, cisplatin, 5-FU, capecitabine |
| Enrollment | 318 |
| Start date | Feb 3, 2015 |
| Primary completion | Jul 23, 2021 |
| Completion | Jul 23, 2021 |
| First posted | Jan 9, 2015 |
| Last update posted | Aug 8, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: